Bill's Feed
Feb 15, 2013

High-stakes cholesterol study could lift Merck cloud

NEW YORK (Reuters) – Favorable results from a huge heart study could help redeem investors’ faith in Merck & Co and its two biggest cholesterol drugs, Vytorin and Zetia, and potentially add billions of dollars in annual revenue.

Investors have soured on the No. 2 U.S. drugmaker since late December, following setbacks to a closely watched experimental drug for osteoporosis and a newer cholesterol medicine.

Feb 14, 2013

Regeneron profit beats Street on Eylea sales strength

By Bill Berkrot

(Reuters) – Regeneron Pharmaceuticals Inc (REGN.O: Quote, Profile, Research, Stock Buzz) on Thursday reported a profit that exceeded Wall Street estimates for the sixth consecutive quarter as sales of its new Eylea eye drug for the leading cause of blindness in the elderly continued to soar.

Eylea, which improves vision in patients with age-related macular degeneration, saw U.S. sales rise to $276 million in the fourth quarter despite major storms that disrupted business in the Northeast during the period. Eylea sales were $244 million in the previous quarter.

Feb 13, 2013

Obama Medicare rebate plan could hurt drug companies

Feb 13 (Reuters) – President Barack Obama’s decision to
spotlight drug rebates as a way to save money on Medicare is
likely to be opposed by the pharmaceutical industry, which could
potentially lose billions of dollars in profits.

In his annual State of the Union speech on Tuesday, Obama
said he would “reduce taxpayer subsidies to prescription drug
companies” to rein in the rising cost of Medicare, the $600
billion healthcare program for the elderly and disabled.

Feb 11, 2013

Eli Lilly CEO says company keeping animal health business

NEW YORK, Feb 11 (Reuters) – Eli Lilly and Co’s
chief executive said his company had no intention of following
Pfizer’s lead by spinning off or selling the company’s
lucrative Elanco animal health unit.

“We’re comfortable with that business and we’re going to
keep it,” Lilly CEO John Lechleiter said definitively on Monday
during a question and answer session at the BIO CEO & Investor
conference in New York.

Feb 7, 2013

Amgen biosimilar push takes aim at blockbusters

NEW YORK (Reuters) – Amgen Inc (AMGN.O: Quote, Profile, Research, Stock Buzz) said on Thursday that between this year and 2016 it will have key late-stage data from eight experimental medicines, and that it expects generic versions of biotech drugs, known as biosimilars, to be a multibillion-dollar opportunity for the company.

Amgen Chief Executive Robert Bradway, at a meeting in New York to update analysts and investors on business strategy, said the company plans to launch six biosimilars beginning in 2017 – four cancer drugs and two for inflammatory diseases.

Feb 7, 2013

Amgen outlines pipeline, sees push into biosimilars

NEW YORK (Reuters) – Amgen Inc (AMGN.O: Quote, Profile, Research, Stock Buzz) said on Thursday that between this year and 2016 it will have key late-stage data from eight experimental medicines, and that it expects generic versions of biotech drugs, known as biosimilars, to be a multi-billion dollar opportunity for the company.

Amgen Chief Executive Robert Bradway, at a meeting in New York with analysts and investors to provide an update to its business strategy, said the company plans to launch six biosimilars beginning in 2017 – four cancer drugs and two for inflammatory diseases.

Feb 4, 2013

Life Tech says all ideas on table in strategic review

Feb 4 (Reuters) – Life Technologies Inc, which is
undergoing a strategic review that could lead to the company’s
sale, said on Monday its board had made no decisions and it was
open to all options.

Life Tech, which noted that the process began last summer
when company shares were trading in the $40 range, said the
board review was ongoing.

Jan 31, 2013

PerkinElmer 4th quarter profit tops Street

Jan 31 (Reuters) – PerkinElmer Inc on Thursday
reported higher-than-expected fourth-quarter profit, but the
maker of scientific instruments issued a 2013 earnings forecast
range with a midpoint below Wall Street estimates.

For 2013, the company forecast adjusted earnings of $2.24 to
$2.32 per share and organic revenue to rise in the mid-single
digit range. PerkinElmer would have to hit the top of that range
to meet current Wall Street expectations, according to Thomson
Reuters I/B/E/S.

Jan 31, 2013

Thermo Fisher expects sequestration, 5 percent cut in U.S. budget

By Ransdell Pierson and Bill Berkrot

(Reuters) – Thermo Fisher Scientific Inc’s (TMO.N: Quote, Profile, Research, Stock Buzz) 2013 earnings forecast assumes automatic U.S. government spending cuts will occur in March and decrease the federal budget by more than 5 percent between March and September, the world’s largest maker of laboratory equipment said on Thursday.

The 2013 forecast, which was roughly in line with Wall Street estimates, came as Thermo Fisher reported a higher-than-expected fourth-quarter profit.

Jan 31, 2013

Thermo Fisher expects sequestration, 5 pct cut in US budget

Jan 31 (Reuters) – Thermo Fisher Scientific Inc’s
2013 earnings forecast assumes automatic U.S. government
spending cuts will occur in March and decrease the federal
budget by more than 5 percent between March and September, the
world’s largest maker of laboratory equipment said on Thursday.

The 2013 forecast, which was roughly in line with Wall
Street estimates, came as Thermo Fisher reported a
higher-than-expected fourth-quarter profit.

    • About Bill

      "Based in New York, I primarily cover the pharmaceutical and biotechnology sectors as well as other publicly traded companies involved in health care. Previously covered a wide range of sports for Reuters."
    • Follow Bill